Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Autolus Therapeutics (AUTL) Current Leases: 2019-2025

Historic Current Leases for Autolus Therapeutics (AUTL) over the last 6 years, with Sep 2025 value amounting to $4.8 million.

  • Autolus Therapeutics' Current Leases rose 35.31% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.8 million, marking a year-over-year increase of 35.31%. This contributed to the annual value of $3.0 million for FY2024, which is 40.67% down from last year.
  • Per Autolus Therapeutics' latest filing, its Current Leases stood at $4.8 million for Q3 2025, which was up 47.33% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Autolus Therapeutics' Current Leases peaked at $17.3 million during Q3 2021, and registered a low of -$769,000 during Q2 2021.
  • For the 3-year period, Autolus Therapeutics' Current Leases averaged around $4.4 million, with its median value being $4.8 million (2024).
  • As far as peak fluctuations go, Autolus Therapeutics' Current Leases plummeted by 99.60% in 2021, and later surged by 4,224.29% in 2022.
  • Over the past 5 years, Autolus Therapeutics' Current Leases (Quarterly) stood at $4.5 million in 2021, then climbed by 13.14% to $5.0 million in 2022, then rose by 0.30% to $5.1 million in 2023, then crashed by 40.67% to $3.0 million in 2024, then spiked by 35.31% to $4.8 million in 2025.
  • Its last three reported values are $4.8 million in Q3 2025, $3.3 million for Q2 2025, and $3.0 million during Q1 2025.